EGF and cancer: However, given the long-established oncogenic role that EGF receptor activation plays in human cancers, and dramatic responses in patients with cancer to therapies that inhibit oncogenic EGF receptor activation,33 using therapies around activation or reactivation of ubiquitous EGF expression for treatment of kidney disease has the potential for off-target effects.